Altamira Therapeutics (CYTO) has released an update.
Altamira Therapeutics has reported a net loss from continuing operations of $4,339,832 for the first half of 2024, a slight improvement compared to the previous year’s loss of $4,523,866. The company has also seen a reduction in its total comprehensive loss to $4,170,605 from $6,056,483 in the previous year. These financial results reflect the company’s performance and financial position as of June 30, 2024.
For further insights into CYTO stock, check out TipRanks’ Stock Analysis page.
